Place of Origin: | CHINA |
---|---|
Brand Name: | TINGYI |
Certification: | GMP , ISO 9001:2008 |
Model Number: | CAS: 609799-22-6 |
Minimum Order Quantity: | 10g |
Price: | Contact Us |
Packaging Details: | Stealth And Discreet Packaging |
Delivery Time: | Within 7 Working Days |
Payment Terms: | Bank Transfer - Bitcoin - Western Union - MoneyGram |
Supply Ability: | 400 KG/Month |
Product Name: | Tasimelteon | Other Name: | BMS 214778; MA 1; VEC 162 |
---|---|---|---|
MF: | C15H19NO2 | MW: | 245.32 |
Density: | 1.145 | Appearance: | White Powder |
High Light: | pharmaceutical anabolic steroids,pharmaceutical fine chemicals |
USA FDA Approved Sleep Promoting Drug Tasimelteon Raw Powder
Description:
Tasimelteon is a melatonin receptor agonist. Because of the high density of melatonin receptors
in the circadian pacemaker, the suprachiasmatic nucleus, melatonergic actions can phase-shift
circadian rhythms and promote sleep. Tasimelteon was effective in reducing sleep onset latency
(in phase II and III clinical trials) and in resetting the circadian melatonin rhythm (in phase II trials),
which indicated its potential suitability as treatment for jet lag, shift work and circadian rhythm
sleep disorders. Statistically significant improvements in sleep maintenance have also been
observed with the drug. Tasimelteon has been claimed to be useful in the treatment of
depression, and preclinical evidence in this respect is to be confirmed in a phase II clinical trial,
which was ready to be initiated at the time of publication. It is plausible that the drug may be
effective in the treatment of depressive disorders, at least those that are related to circadian
dysfunction, and that it may attenuate sleep problems in depressed patients of different subtypes.
A general suitability in mitigating other symptoms of major depressive disorder cannot be
deduced from the actions of tasimelteon via the melatonin receptors MT1 and MT2. The drug is
well tolerated, does not induce impairment of next-day functioning or dependence, and seems to
be safe in short-term treatment; however, toxicological data would be required for assessing its
long-term safety.
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|